Genetic Complexity in Spondyloarthritis: Contributions of HLA-B Alleles Beyond HLA-B*27 in Romanian Patients
Simple Summary
Abstract
1. Introduction
2. Results
2.1. Demographic and Clinical Characteristics
2.2. HLA-B Allele Distribution in HLA-B*27-Negative SpA Patients
2.3. HLA-B Alleles in Relation to Clinical Subtypes of SpA
2.4. HLA-B Allele Distribution and Clinical Phenotype Correlations
2.5. Comparative HLA-B Allele Frequencies Between Patients and Controls
2.6. Comparative HLA-B Genotypes and Hardy–Weinberg Disequilibrium Between Patients and Controls
2.7. Comparative Peptide-Binding of Risk HLA-B Alleles Versus HLA-B*27
3. Discussions
3.1. Cross-Reactivity and the Diagnostic Hypothesis
3.2. HLA-B*47, B*54, and B*40: Novel Associations Beyond B27
3.2.1. HLA-B47: Association with SpA and Structural Relatedness to HLA-B27
3.2.2. HLA-B*54: A Rare Allele Potentially Involved in axSpA Susceptibility
3.2.3. HLA-B*40: Protective Association in the Studied Romanian Cohort
3.2.4. HLA-B*53: A Modest Frequency Signal of Potential Relevance
3.3. Population-Specific HLA-B Patterns in SpA
3.4. Study Limitations and Further Directions
4. Materials and Methods
4.1. Study Design and Population
4.2. Inclusion and Exclusion Criteria
4.3. Genotyping Protocol
4.4. Statistical Analysis
4.5. Ethical Considerations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
AS | Ankylosing Spondylitis |
ASAS | Assessment of SpondyloArthritis International Society |
ASDAS | Ankylosing Spondylitis Disease Activity Score |
BASDAI | Bath Ankylosing Spondylitis Disease Activity Index |
CD | Cluster of Differentiation |
CI | Confidence Interval |
CREG | Cross-Reactive Group |
CRP | C-reactive Protein |
DPB | Diffuse Panbronchiolitis |
ESR | Erythrocyte Sedimentation Rate |
HLA | Human Leukocyte Antigen |
IBD | Inflammatory Bowel Disease |
IGAS | International Genetics of Ankylosing Spondylitis Consortium |
IL | Interleukin |
MICA | MHC class I chain-related sequence A |
MRI | Magnetic Resonance Imaging |
nr-axSpA | Non-radiographic Axial Spondyloarthritis |
OR | Odds Ratio |
PCR-SSP | Polymerase Chain Reaction with Sequence-Specific Primers |
PsA | Psoriatic Arthritis |
RR | Relative Risk |
ReA | Reactive Arthritis |
SpA | Spondyloarthritis |
TAP | Transporter Associated with Antigen Processing |
TNF | Tumor Necrosis Factor |
USpA | Undifferentiated Spondyloarthritis |
References
- Proft, F.; Poddubnyy, D. Ankylosing Spondylitis and Axial Spondyloarthritis: Recent Insights and Impact of New Classification Criteria. Ther. Adv. Musculoskel. Dis. 2018, 10, 129–139. [Google Scholar] [CrossRef] [PubMed]
- Rudwaleit, M.; van der Heijde, D.; Landewé, R.; Listing, J.; Akkoc, N.; Brandt, J.; Braun, J.; Chou, C.T.; Collantes-Estevez, E.; Dougados, M.; et al. The Development of Assessment of SpondyloArthritis International Society Classification Criteria for Axial Spondyloarthritis (Part II): Validation and Final Selection. Ann. Rheum. Dis. 2009, 68, 777–783. [Google Scholar] [CrossRef] [PubMed]
- Rudwaleit, M.; Van Der Heijde, D.; Landewé, R.; Akkoc, N.; Brandt, J.; Chou, C.T.; Dougados, M.; Huang, F.; Gu, J.; Kirazli, Y.; et al. The Assessment of SpondyloArthritis International Society Classifi Cation Criteria for Peripheral Spondyloarthritis and for Spondyloarthritis in General. Ann. Rheum Dis. 2011, 70, 25–31. [Google Scholar] [CrossRef] [PubMed]
- Brown, M.A.; Li, Z.; Cao, K.A.L. Biomarker Development for Axial Spondyloarthritis. Nat. Rev. Rheumatol. 2020, 16, 448–463. [Google Scholar] [CrossRef]
- Cortes, A.; Hadler, J.; Pointon, J.P.; Robinson, P.C.; Karaderi, T.; Leo, P.; Cremin, K.; Pryce, K.; Harris, J.; Lee, S.; et al. Identification of Multiple Risk Variants for Ankylosing Spondylitis through High-Density Genotyping of Immune-Related Loci. Nat. Genet. 2013, 45, 730–738. [Google Scholar] [CrossRef]
- Levering, W.H.B.M.; Wind, H.; Sintnicolaas, K.; Hooijkaas, H.; Gratama, J.W. Flow Cytometric HLA-B27 Screening: Cross-Reactivity Patterns of Commercially Available Anti—HLA-B27 Monoclonal Antibodies with Other HLA-B Antigens. Clin. Cytom. 2003, 54B, 28–38. [Google Scholar] [CrossRef]
- Cianga, P.; Zlei, M.; Rezus, E.; Cianga, C. The Flow Cytometric Labeling Pattern in HLA-B27 Detection May Suggest Cross Reactivities. Rev. Română Med. Lab. 2011, 19, 185–191. [Google Scholar]
- Constantinescu, I.; Boșcaiu, V.; Cianga, P.; Dinu, A.A.; Gai, E.; Melinte, M.; Moise, A. The Frequency of HLA Alleles in the Romanian Population. Immunogenetics 2016, 68, 167–178. [Google Scholar] [CrossRef]
- Arnett, F.C., Jr.; Hochberg, M.C.; Bias, W.B. Cross-Reactive HLA Antigens in B27-Negative Reiter’s Syndrome and Sacroiliitis. Johns Hopkins Med. J. 1977, 141, 193–197. [Google Scholar]
- Siala, M.; Mahfoudh, N.; Fourati, H.; Gdoura, R.; Younes, M.; Kammoun, A.; Chour, I.; Meddeb, N.; Gaddour, L.; Hakim, F.; et al. MHC Class I and Class II Genes in Tunisian Patients with Reactive and Undifferentiated Arthritis. Clin. Exp. Immunol. 2009, 27, 208–213. [Google Scholar]
- Sampaio-Barros, P.D.; Conde, R.A.; Donadi, E.A.; Kraemer, M.H.S.; Persoli, L.; Coimbra, I.B.; Costallat, L.T.L.; Samara, A.M.; Bértolo, M.B. Undifferentiated Spondyloarthropathies in Brazilians: Importance of HLA-B27 and the B7-CREG Alleles in Characterization and Disease Progression. J. Rheumatol. 2003, 30, 2632–2637. [Google Scholar]
- Parasannanavar, D.J.; Rajadhyaksha, A.; Ghosh, K. Role of HLA-B Alleles and Clinical Presentation of B27 Negative Spondyloarthritis Patients from Mumbai, Western India. Autoimmune Dis. 2014, 2014, 327315. [Google Scholar] [CrossRef] [PubMed]
- Cortes, A.; Pulit, S.L.; Leo, P.J.; Pointon, J.J.; Robinson, P.C.; Weisman, M.H.; Ward, M.; Gensler, L.S.; Zhou, X.; Garchon, H.; et al. Major Histocompatibility Complex Associations of Ankylosing Spondylitis Are Complex and Involve Further Epistasis with ERAP1. Nat. Commun. 2015, 6, 7146. [Google Scholar] [CrossRef] [PubMed]
- Reveille, J.D.; Zhou, X.; Lee, M.; Weisman, M.H.; Yi, L.; Gensler, L.S.; Zou, H.; Ward, M.M.; Ishimori, M.L.; Learch, T.J.; et al. HLA Class I and II Alleles in Susceptibility to Ankylosing Spondylitis. Ann. Rheum Dis. 2018, 78, 66–73. [Google Scholar] [CrossRef]
- Cedoz, J.P.; Wendling, D.; Viel, J.F. The B7 Cross Reactive Group and Spondyloarthropathies: An Epidemiological Approach. J Rheumatol. 1995, 22, 1884–1890. [Google Scholar]
- Khan, B.Y.M.A. B7-CREG and Ankylosing Spondylitis. Br. J. Rheumatol. 1983, 22, 129–133. [Google Scholar] [CrossRef]
- Chen, J.; Yang, F.; Zhang, Y.; Fan, X.; Xiao, H.; Qian, W.; Chang, Y. HLA-A * 01: 01 in MHC Is Associated with Psoriatic Arthritis in Chinese Han Population. Arch. Dermatol. Res. 2019, 311, 277–285. [Google Scholar] [CrossRef]
- Breban, M. Genetic Studies of Spondylarthropathies. French Spondylarthropathy Genetic Study Group. Ann. Med. Interne 1998, 149, 142–144. [Google Scholar]
- Lo, C.; Mijiyawa, M.; Gonza, S.; Ferna, J.L.; Blanco-gelaz, M.A. Association of Ankylosing Spondylitis With HLA-B*1403 in a West African Population. Arthritis Rheum. 2002, 46, 2968–2971. [Google Scholar] [CrossRef]
- Mielants, H.; Veys, E.M.; Cuvelier, C.; Vos, M.D.E. Ileocolonoscopic Findings in Seronegative Spondylarthropathies. Br. J. Rheumatol. 1988, 27, 95–105. [Google Scholar] [CrossRef]
- Vargas-Alarcón, G.; Londoño, J.D.; Hernández-Pacheco, G.; Pacheco-Tena, C.; Castillo, E.; Cardiel, M.H.; Granados, J.; Burgos-Vargas, R. Effect of HLA-B and HLA-DR Genes on Susceptibility to and Severity of Spondyloarthropathies in Mexican Patients. Ann. Rheum Dis. 2002, 61, 714–717. [Google Scholar] [CrossRef] [PubMed]
- Santos, A.M.; Peña, P.; Avila, M.; Briceño, I.; Jaramillo, C.; Vargas-alarcon, G.; Rueda, J.C.; Saldarriaga, E.; Angarita, J.; Martinez-rodriguez, N.; et al. Association of Human Leukocyte A, B, and DR Antigens in Colombian Patients with Diagnosis of Spondyloarthritis. Clin. Rheumatol. 2017, 36, 953–958. [Google Scholar] [CrossRef] [PubMed]
- Šegota, A.; Schnurrer-Luke-Vrbanić, T.; Avancini-Dobrović, V.; Mirić, F. Clinical Significance of Possible HLA Biomarkers in Axial Spondyloarthritis beyond HLA-B27 Positivity. Rheumatol. Int. 2023, 43, 2073–2079. [Google Scholar] [CrossRef] [PubMed]
- Pavlica, L.; Perić-Hajzler, Z.; Jovelić, A.; Sekler, B.; Damjanović, M. Psoriatic Arthritis: A Retrospective Study of 162 Patients. Vojnosanit. Pregl. 2005, 62, 613–620. [Google Scholar] [CrossRef]
- Šošo, D.; Aljinović, J.; Marinović, I.; Kojundžić, S.L.; Jeličić, E.Č.; Krstulović, D.M. The Occurrence of Sacroiliitis in HLA-B*35-Positive Patients with Undifferentiated Spondyloarthritis. A Cross Sectional MRI Study. Clin. Rheumatol. 2020, 39, 2299–2306. [Google Scholar] [CrossRef]
- Said-Nahal, R.; Miceli-Richard, C.; Berthelot, J.M.; Duché, A.; Dernis-Labous, E.; Le Blévec, G.; Saraux, A.; Perdriger, A.; Guis, S.; Claudepierre, P.; et al. The Familial Form of Spondylarthropathy: A Clinical Study of 115 Multiplex Families. Groupe Français d’Etude Génétique Des Spondylarthropathies. Arthritis Rheum. 2000, 43, 1356–1365. [Google Scholar] [CrossRef]
- Díaz-Peña, R.; Vidal-Castiñeira, J.R.; López-Larrea, C. HLA-B * 40: 01 Is Associated with Ankylosing Spondylitis in HLA-B27−Positive Populations. J. Rheumatol. 2016, 43, 1255–1256. [Google Scholar] [CrossRef]
- Schneeberger, E.E.; Citera, G.; Gil, G.R.; Granel, A.; Arturi, A.; Rosemffet, G.M.; Antonio, J.; Cocco, M.; Berman, A.; Spindler, A.; et al. Clinical and Immunogenetic Characterization in Psoriatic Arthritis Patients. Clin. Rheumatol. 2014, 34, 1413–1418. [Google Scholar] [CrossRef]
- Eder, L.; Chandran, V.; Pellett, F.; Shanmugarajah, S.; Rosen, C.F.; Bull, S.B.; Gladman, D.D. Differential Human Leucocyte Allele Association between Psoriasis and Psoriatic Arthritis: A Family-Based Association Study. Ann. Rheum. Dis. 2012, 71, 1361–1366. [Google Scholar] [CrossRef]
- Yamaguchi, A.; Tsuchiya, N.; Mitsui, H.; Shiota, M. Association of HLA-B39 with HLA-B27-Negative Ankylosing Spondylitis and Pauciarticular Juvenile Rheumatoid Arthritis in Japanese Patients. Evidence for a Role of the Peptide-Anchoring B Pocket. Arthritis Rheum. 1995, 38, 1672–1677. [Google Scholar] [CrossRef]
- Brown, M.A.; Pile, K.D.; Kennedy, L.G.; Calin, A.; Darke, C.; Bell, J.; Wordsworth, B.P.; Come, F.; Cornélis, F. HLA Class I Associations of Ankylosing Spondylitis in the White Population in the United Kingdom. Ann. Rheum. Dis. 1996, 55, 268–270. [Google Scholar] [CrossRef] [PubMed]
- Wei, J.C.C.; Tsai, W.C.; Lin, H.S.; Tsai, C.Y.; Chou, C.T. HLA-B60 and B61 Are Strongly Associated with Ankylosing Spondylitis in HLA-B27-Negative Taiwan Chinese Patients. Rheumatology 2004, 43, 839–842. [Google Scholar] [CrossRef] [PubMed]
- Wang, G.; Kim, T.H.; Li, Z.; Cortes, A.; Kim, K.; Bang, S.Y.; Leo, P.; Brown, M.A.; Xu, H. MHC Associations of Ankylosing Spondylitis in East Asians Are Complex and Involve Non-HLA-B27 HLA Contributions. Arthritis Res. Ther. 2020, 22, 74. [Google Scholar] [CrossRef] [PubMed]
- Khoshbakht, S.; Başkurt, D.; Vural, A.; Vural, S. Behçet’s Disease: A Comprehensive Review on the Role of HLA-B*51, Antigen Presentation, and Inflammatory Cascade. Int. J. Mol. Sci. 2023, 24, 16382. [Google Scholar] [CrossRef]
- Lim, M.J.; Noh, E.; Lee, R.W.; Jung, K.H.; Park, W. Occurrence of Human Leukocyte Antigen B51-Related Ankylosing Spondylitis in a Family: Two Case Reports. World J. Clin. Cases 2022, 10, 992–999. [Google Scholar] [CrossRef]
- Díaz-Peña, R.; Blanco-Gelaz, M.A.; Njobvu, P.; López-Vazquez, A.; Suárez-Alvarez, B.; Díaz-peña, R.; Blanco-gelaz, M.A.; Njobvu, P.; López-Vazquez, A.; Suárez-Alvarez, B.; et al. Influence of HLA-B * 5703 and HLA-B * 1403 on Susceptibility to Spondyloarthropathies in the Zambian Population. J. Rheumatol. 2008, 35, 2236–2240. [Google Scholar] [CrossRef]
- van Deutekom, H.W.M.; Keşmir, C. Zooming into the Binding Groove of HLA Molecules: Which Positions and Which Substitutions Change Peptide Binding Most? Immunogenetics 2015, 67, 425–436. [Google Scholar] [CrossRef]
- Nguyen, A.T.; Szeto, C.; Gras, S. The Pockets Guide to HLA Class I Molecules. Biochem. Soc. Trans. 2021, 49, 2319–2331. [Google Scholar] [CrossRef]
- Cobos-Figueroa, L.; Robles-Parrado, J.; Alari-Pahissa, E.; Galocha, B.; Mir, C.; Pintor-Poveda, A.; Barnea, E.; Admon, A.; Lauzurica, P.; Lorente, E. Closer Peptide Repertoire Similarity of HLA-B∗14:03 and HLA-B∗27:05 Sheds Light on Ankylosing Spondylitis Susceptibility. Mol. Cell. Proteom. 2025, 24, 101008. [Google Scholar] [CrossRef]
- Sun, L.; Hebert, A.S.; Yan, X.; Zhao, Y.; Westphall, M.S.; Rush, M.J.P.; Zhu, G.; Champion, M.M.; Coon, J.J.; Dovichi, N.J. Over 10,000 Peptide Identifications from the HeLa Proteome by Using Single-Shot Capillary Zone Electrophoresis Combined with Tandem Mass Spectrometry. Angew. Chem. Int. Ed. Engl. 2014, 53, 13931–13933. [Google Scholar] [CrossRef]
- Hansen, T.; Bratlie, A.; Hannestad, K. Four Cytotoxic Human-Human Hybridoma Antibodies That React with HLA-B27. Tissue Antigens 1988, 32, 267–277. [Google Scholar] [CrossRef]
- Turowska-Heydel, D.; Pietrzyk, J.J.; Turowski, G. [HLA haplotypes in families of children with congenital adrenal hyperplasia]. Pediatr. Pol. 1995, 70, 115–120. [Google Scholar]
- Hildebrand, W.H.; Madrigal, J.A.; Little, A.M.; Parham, P. HLA-Bw22: A Family of Molecules with Identity to HLA-B7 in the Alpha 1-Helix. J. Immunol. 1992, 148, 1155–1162. [Google Scholar] [CrossRef]
- Shen, C.; She, J. [Human leukocyte antigen genes to genetic predisposition in diffuse panbronchiolitis]. Zhonghua Jie He He Hu Xi Za Zhi 2008, 31, 272–276. [Google Scholar] [PubMed]
- Poletti, V.; Casoni, G.; Chilosi, M.; Zompatori, M. Diffuse Panbronchiolitis. Eur. Respir. J. 2006, 28, 862–871. [Google Scholar] [CrossRef] [PubMed]
- Met, C.M.; Hofstaedter, C.E.; O’Keefe, I.P.; Yang, H.; Moustafa, D.A.; Sherman, M.E.; Doi, Y.; Rasko, D.A.; Sweet, C.R.; Goldberg, J.B.; et al. Characterization of Pseudomonas Aeruginosa from Subjects with Diffuse Panbronchiolitis. Microbiol. Spectr. 2024, 12, e0053024. [Google Scholar] [CrossRef] [PubMed]
- Asakawa, J.; Kobayashi, S.; Kaneda, K.; Ogasawara, H.; Sugawara, M.; Yasuda, M.; Hashimoto, H. Reactive Arthritis after Influenza Vaccination: Report of a Case. Mod. Rheumatol. 2005, 15, 283–285. [Google Scholar] [CrossRef]
- Matzaraki, V.; Kumar, V.; Wijmenga, C.; Zhernakova, A. The MHC Locus and Genetic Susceptibility to Autoimmune and Infectious Diseases. Genome Biol. 2017, 18, 76. [Google Scholar] [CrossRef]
- Trowsdale, J.; Knight, J.C. Major Histocompatibility Complex Genomics and Human Disease. Annu. Rev. Genom. Hum. Genet. 2013, 14, 301–323. [Google Scholar] [CrossRef]
- Croitoru, C.G.; Constantinescu, D.; Pavel-Tanasa, M.; Cuciureanu, D.I.; Cianga, C.M.; Hodorog, D.N.; Cianga, P. HLA Class I and II Alleles in Anti-Acetylcholine Receptor Antibodies Positive and Double-Seronegative Myasthenia Gravis Patients of Romanian Descent. Neurol. Int. 2024, 16, 1819–1836. [Google Scholar] [CrossRef]
- Myers, T.A.; Chanock, S.J.; Machiela, M.J. LDlinkR: An R Package for Rapidly Calculating Linkage Disequilibrium Statistics in Diverse Populations. Front. Genet. 2020, 11, 157. [Google Scholar] [CrossRef]
- Auton, A.; Brooks, L.D.; Durbin, R.M.; Garrison, E.P.; Kang, H.M.; Korbel, J.O.; Marchini, J.L.; McCarthy, S.; McVean, G.A.; Abecasis, G.R. A Global Reference for Human Genetic Variation. Nature 2015, 526, 68–74. [Google Scholar] [CrossRef] [PubMed]
- Chimenti, M.S.; Perricone, C.; D’Antonio, A.; Ferraioli, M.; Conigliaro, P.; Triggianese, P.; Ciccacci, C.; Borgiani, P.; Perricone, R. Genetics, Epigenetics, and Gender Impact in Axial-Spondyloarthritis Susceptibility: An Update on Genetic Polymorphisms and Their Sex Related Associations. Front. Genet. 2021, 12, 671976. [Google Scholar] [CrossRef] [PubMed]
- Wang, Q.; Zhou, X. Associations of MICA Polymorphisms with Inflammatory Rheumatic Diseases. Open Rheumatol. J. 2015, 9, 94–100. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Lazaro, A.M.; Lavingia, B.; Stastny, P. Typing for All Known MICA Alleles by Group-Specific PCR and SSOP. Hum. Immunol. 2001, 62, 620–631. [Google Scholar] [CrossRef]
- Petersdorf, E.W.; Shuler, K.B.; Longton, G.M.; Spies, T.; Hansen, J.A. Population Study of Allelic Diversity in the Human MHC Class I-Related MIC-A Gene. Immunogenetics 1999, 49, 605–612. [Google Scholar] [CrossRef]
- Chen, J.J.; Hollenbach, J.A.; Trachtenberg, E.A.; Just, J.J.; Carrington, M.; Rønningen, K.S.; Begovich, A.; King, M.C.; McWeeney, S.; Mack, S.J.; et al. Hardy-Weinberg Testing for HLA Class II (DRB1, DQA1, DQB1, and DPB1) Loci in 26 Human Ethnic Groups. Tissue Antigens 1999, 54, 533–542. [Google Scholar] [CrossRef]
Category | Clinical Feature | n (%) |
---|---|---|
Musculoskeletal | Inflammatory low back pain | 185 (70.3%) |
Peripheral joint involvement | 187 (71.1%) | |
Lower limb involvement | 157 (59.7%) | |
Upper limb involvement | 118 (44.9%) | |
Abnormal spinal mobility (Schober < 5 cm) | 208 (79.1%) | |
Enthesitis | 41 (15.6%) | |
Dactylitis | 15 (5.7%) | |
Heel pain | 47 (17.9%) | |
Extra-articular | Psoriasis | 33 (12.5%) |
Uveitis | 25 (9.5%) | |
Inflammatory bowel disease | 7 (2.7%) | |
Laboratory | Elevated CRP or ESR | 78 (29.7%) |
Imaging | Sacroiliitis (grade ≥ 2) | 90 (34.2%) |
MRI-detectable lesions or grade 1 changes | 108 (41.1%) | |
Symmetrical sacroiliitis | 118 (44.9%) |
HLA-B | AS (n = 65) | nr-axSpA (n = 41) | PsA (n = 34) | ReA (n = 5) | USpA (n = 116) | p-Value | Bootstrap p-Value |
---|---|---|---|---|---|---|---|
HLA-B*07 | 10 (15.38%) | 9 (21.95%) | 6 (17.65%) | 0 (0%) | 12 (10.34%) | 0.3220 | 0.441 |
HLA-B*08 | 12 (18.46%) | 7 (17.07%) | 7 (20.59%) | 1 (20%) | 18 (15.52%) | 0.9626 | 0.273 |
HLA-B*13 | 7 (10.77%) | 3 (7.32%) | 6 (17.65%) | 0 (0%) | 12 (10.34%) | 0.5890 | 0.729 |
HLA-B*14 | 4 (6.15%) | 2 (4.88%) | 3 (8.82%) † | 0 (0%) | 1 (0.86%) | 0.1746 | 0.305 (0.040 †) |
HLA-B*15 | 5 (7.69%) | 1 (2.44%) | 2 (5.88%) | 0 (0%) | 11 (9.48%) | 0.5979 | 0.700 |
HLA-B*18 | 17 (26.15%) | 7 (17.07%) | 4 (11.76%) | 1 (20%) | 30 (25.86%) | 0.3807 | 0.472 |
HLA-B*35 | 14 (21.54%) | 15 (36.59%) | 8 (23.53%) | 0 (0%) | 38 (32.76%) | 0.1805 | 0.173 |
HLA-B*37 | 1 (1.54%) | 0 (0%) | 0 (0%) | 1 (20%) † | 2 (1.72%) | 0.0140 | 0.437 (0.045 †) |
HLA-B*38 | 5 (7.69%) | 5 (12.2%) | 2 (5.88%) | 1 (20%) | 13 (11.21%) | 0.7368 | 0.879 |
HLA-B*39 | 2 (3.08%) | 0 (0%) | 2 (5.88%) | 0 (0%) | 7 (6.03%) | 0.4904 | 0.492 |
HLA-B*40 | 6 (9.23%) | 1 (2.44%) | 3 (8.82%) | 1 (20%) | 6 (5.17%) | 0.4006 | 0.669 |
HLA-B*41 | 2 (3.08%) | 2 (4.88%) | 2 (5.88%) | 2 (40%) † | 4 (3.45%) | 0.0045 | 0.325 (0.005 †) |
HLA-B*44 | 10 (15.38%) | 2 (4.88%) | 8 (23.53%) | 1 (20%) | 17 (14.66%) | 0.2447 | 0.116 |
HLA-B*47 | 3 (4.62%) | 2 (4.88%) | 1 (2.94%) | 0 (0%) | 6 (5.17%) | 0.9686 | 0.986 |
HLA-B*48 | 1 (1.54%) | 1 (2.44%) | 0 (0%) | 0 (0%) | 1 (0.86%) | 0.8741 | 0.955 |
HLA-B*49 | 2 (3.08%) | 3 (7.32%) | 1 (2.94%) | 1 (20%) | 4 (3.45%) | 0.3335 | 0.782 |
HLA-B*50 | 4 (6.15%) | 1 (2.44%) | 1 (2.94%) | 0 (0%) | 3 (2.59%) | 0.7324 | 0.910 |
HLA-B*51 | 9 (13.85%) | 3 (7.32%) | 4 (11.76%) | 0 (0%) | 22 (18.97%) | 0.3273 | 0.402 |
HLA-B*52 | 4 (6.15%) | 5 (12.2%) † | 2 (5.88%) | 0 (0%) | 1 (0.86%) | 0.0437 | 0.110 (0.013 †) |
HLA-B*53 | 1 (1.54%) | 1 (2.44%) | 1 (2.94%) | 0 (0%) | 1 (0.86%) | 0.8953 | 0.978 |
HLA-B*54 | 1 (1.54%) | 0 (0%) | 1 (2.94%) | 0 (0%) | 1 (0.86%) | 0.7968 | 0.657 |
HLA-B*55 | 1 (1.54%) | 2 (4.88%) | 1 (2.94%) | 0 (0%) | 2 (1.72%) | 0.7848 | 0.967 |
HLA-B*56 | 2 (3.08%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (2.59%) | 0.6796 | 0.701 |
HLA-B*57 | 3 (4.62%) | 1 (2.44%) | 2 (5.88%) | 0 (0%) | 3 (2.59%) | 0.8383 | 0.948 |
HLA-B*58 | 1 (1.54%) | 1 (2.44%) | 1 (2.94%) | 0 (0%) | 2 (1.72%) | 0.9808 | 0.997 |
HLA-B | Axial (n = 68) | Peripheral (n = 56) | Mixed (n = 139) | p-Value |
---|---|---|---|---|
HLA-B*07 | 11 (16.18%) | 7 (12.5%) | 19 (13.67%) | 0.8260 |
HLA-B*08 | 11 (16.18%) | 13 (23.21%) | 23 (16.55%) | 0.4995 |
HLA-B*13 | 7 (10.29%) | 7 (12.5%) | 14 (10.07%) | 0.8784 |
HLA-B*14 | 3 (4.41%) | 3 (5.36%) | 4 (2.88%) | 0.6825 |
HLA-B*15 | 3 (4.41%) | 6 (10.71%) | 10 (7.19%) | 0.4024 |
HLA-B*18 | 14 (20.59%) | 11 (19.64%) | 34 (24.46%) | 0.7005 |
HLA-B*35 | 22 (32.35%) | 13 (23.21%) | 40 (28.78%) | 0.5305 |
HLA-B*37 | 1 (1.47%) | 2 (3.57%) | 1 (0.72%) | 0.3380 |
HLA-B*38 | 6 (8.82%) | 3 (5.36%) | 17 (12.23%) | 0.3274 |
HLA-B*39 | 2 (2.94%) | 4 (7.14%) | 5 (3.6%) | 0.4482 |
HLA-B*40 | 4 (5.88%) | 3 (5.36%) | 10 (7.19%) | 0.8719 |
HLA-B*41 | 1 (1.47%) | 4 (7.14%) | 7 (5.04%) | 0.2981 |
HLA-B*44 | 10 (14.71%) | 10 (17.86%) | 19 (13.67%) | 0.7575 |
HLA-B*47 | 4 (5.88%) | 2 (3.57%) | 6 (4.32%) | 0.8115 |
HLA-B*48 | 0 (0%) | 1 (1.79%) | 2 (1.44%) | 0.5767 |
HLA-B*49 | 4 (5.88%) | 1 (1.79%) | 6 (4.32%) | 0.5222 |
HLA-B*50 | 3 (4.41%) | 1 (1.79%) | 5 (3.6%) | 0.7160 |
HLA-B*51 | 7 (10.29%) | 12 (21.43%) | 19 (13.67%) | 0.1994 |
HLA-B*52 | 4 (5.88%) | 1 (1.79%) | 7 (5.04%) | 0.5129 |
HLA-B*53 | 2 (2.94%) | 0 (0%) | 2 (1.44%) | 0.4092 |
HLA-B*54 | 3 (4.41%) | 0 (0%) | 0 (0%) | 0.0030 |
HLA-B*55 | 2 (2.94%) | 0 (0%) | 4 (2.88%) | 0.4356 |
HLA-B*56 | 3 (4.41%) | 1 (1.79%) | 1 (0.72%) | 0.1880 |
HLA-B*57 | 1 (1.47%) | 2 (3.57%) | 6 (4.32%) | 0.5701 |
HLA-B*58 | 3 (4.41%) | 1 (1.79%) | 1 (0.72%) | 0.1880 |
HLA-B | Control #1 (n = 335) | SpA (n = 263) | p-Value | RR [95% CI] |
---|---|---|---|---|
HLA-B*07 | 38 (11.34%) | 37 (14.07%) | 0.3228 | 1.240 [0.813–1.893] |
HLA-B*08 | 52 (15.52%) | 47 (17.87%) | 0.5062 | 1.151 [0.803–1.650] |
HLA-B*13 | 31 (9.25%) | 28 (10.65%) | 0.5832 | 1.150 [0.708–1.868] |
HLA-B*14 | 15 (4.48%) | 10 (3.8%) | 0.8375 | 0.849 [0.388–1.860] |
HLA-B*15 | 35 (10.45%) | 19 (7.22%) | 0.1968 | 0.692 [0.405–1.180] |
HLA-B*18 | 74 (22.09%) | 59 (22.43%) | 0.9215 | 1.016 [0.751–1.373] |
HLA-B*35 | 99 (29.55%) | 75 (28.52%) | 0.7865 | 0.965 [0.749–1.243] |
HLA-B*37 | 8 (2.39%) | 4 (1.52%) | 0.5637 | 0.637 [0.194–2.093] |
HLA-B*38 | 34 (10.15%) | 26 (9.89%) | 1.0000 | 0.974 [0.600–1.581] |
HLA-B*39 | 16 (4.78%) | 11 (4.18%) | 0.8435 | 0.876 [0.413–1.855] |
HLA-B*40 | 32 (9.55%) | 17 (6.46%) | 0.1802 | 0.677 [0.384–1.192] |
HLA-B*41 | 9 (2.69%) | 12 (4.56%) | 0.2647 | 1.698 [0.726–3.971] |
HLA-B*44 | 62 (18.51%) | 39 (14.83%) | 0.2716 | 0.801 [0.555–1.156] |
HLA-B*47 | 4 (1.19%) | 12 (4.56%) | 0.0189 | 3.821 [1.246–11.720] |
HLA-B*48 | 0 (0%) | 3 (1.14%) | 0.0845 | - |
HLA-B*49 | 16 (4.78%) | 11 (4.18%) | 0.8435 | 0.876 [0.413–1.855] |
HLA-B*50 | 4 (1.19%) | 9 (3.42%) | 0.0886 | 2.866 [0.892–9.206] |
HLA-B*51 | 61 (18.21%) | 38 (14.45%) | 0.2253 | 0.794 [0.547–1.151] |
HLA-B*52 | 19 (5.67%) | 12 (4.56%) | 0.5823 | 0.805 [0.397–1.628] |
HLA-B*53 | 0 (0%) | 4 (1.52%) | 0.0369 | - |
HLA-B*54 | 0 (0%) | 2 (0.76%) | 0.0845 | - |
HLA-B*55 | 10 (2.99%) | 7 (2.66%) | 0.7995 | 0.764 [0.281–2.076] |
HLA-B*56 | 5 (1.49%) | 5 (1.9%) | 0.7553 | 1.274 [0.373–4.355] |
HLA-B*57 | 8 (2.39%) | 9 (3.42%) | 0.4679 | 1.433 [0.560–3.664] |
HLA-B*58 | 13 (3.88%) | 5 (1.9%) | 0.2278 | 0.490 [0.177–1.357] |
HLA-B*73 | 2 (0.6%) | 0 (0%) | 0.5064 | - |
HLA-B | Control #2 (n = 1705) | SpA (n = 263) | p-Value | RR [95% CI] |
---|---|---|---|---|
HLA-B*07 | 188 (11.03%) | 37 (14.07%) | 0.1462 | 1.276 [0.919–1.771] |
HLA-B*08 | 297 (17.42%) | 47 (17.87%) | 0.8616 | 1.026 [0.776–1.356] |
HLA-B*13 | 138 (8.09%) | 28 (10.65%) | 0.1887 | 1.315 [0.895–1.933] |
HLA-B*14 | 85 (4.99%) | 10 (3.8%) | 0.5354 | 0.763 [0.401–1.450] |
HLA-B*15 | 149 (8.74%) | 19 (7.22%) | 0.4774 | 0.827 [0.522–1.309] |
HLA-B*18 | 331 (19.41%) | 59 (22.43%) | 0.2460 | 1.156 [0.905–1.476] |
HLA-B*35 | 444 (26.04%) | 75 (28.52%) | 0.4085 | 1.095 [0.889–1.348] |
HLA-B*37 | 32 (1.88%) | 4 (1.52%) | 1.000 | 0.814 [0.289–2.273] |
HLA-B*38 | 144 (8.45%) | 26 (9.89%) | 0.4114 | 1.171 [0.787–1.741] |
HLA-B*39 | 88 (5.16%) | 11 (4.18%) | 0.6486 | 0.810 [0.438–1.496] |
HLA-B*40 | 185 (10.85%) | 17 (6.46%) | 0.0287 | 0.596 [0.369–0.962] |
HLA-B*41 | 70 (4.11%) | 12 (4.56%) | 0.7397 | 1.111 [0.611–2.022] |
HLA-B*44 | 321 (18.83%) | 39 (14.83%) | 0.1236 | 0.787 [0.580–1.070] |
HLA-B*47 | 21 (1.23%) | 12 (4.56%) | 0.0007 | 3.705 [1.844–7.441] |
HLA-B*48 | 7 (0.41%) | 3 (1.14%) | 0.1387 | 2.778 [0.723–10.68] |
HLA-B*49 | 51 (2.99%) | 11 (4.18%) | 0.3400 | 1.396 [0.738–2.648] |
HLA-B*50 | 52 (3.05%) | 9 (3.42%) | 0.7031 | 1.122 [0.560–2.250] |
HLA-B*51 | 316 (18.53%) | 38 (14.45%) | 0.1204 | 0.777 [0.572–1.063] |
HLA-B*52 | 99 (5.81%) | 12 (4.56%) | 0.4751 | 0.786 [0.438–1.411] |
HLA-B*53 | 11 (0.59%) | 4 (1.52%) | 0.1292 | 2.357 [0.756–7.351] |
HLA-B*54 | 1 (0.06%) | 2 (0.76%) | 0.0085 | 19.45 [2.029–186.4] |
HLA-B*55 | 52 (3.05%) | 7 (2.66%) | 0.6940 | 0.748 [0.325–1.724] |
HLA-B*56 | 38 (2.23%) | 5 (1.9%) | 1.000 | 0.853 [0.339–2.148] |
HLA-B*57 | 59 (3.46%) | 9 (3.42%) | 1.000 | 0.989 [0.496–1.970] |
HLA-B*58 | 50 (2.93%) | 5 (1.9%) | 0.4253 | 0.648 [0.261–1.624] |
HLA-B*73 | 2 (0.12%) | 0 (0%) | 1.000 | - |
HLA-B | Control #3 (n = 2040) | SpA (n = 263) | p-Value | RR [95% CI] |
---|---|---|---|---|
HLA-B*07 | 226 (11.08%) | 37 (14.07%) | 0.1462 | 1.276 [0.919–1.771] |
HLA-B*08 | 349 (17.11%) | 47 (17.87%) | 0.8616 | 1.026 [0.776–1.356] |
HLA-B*13 | 169 (8.28%) | 28 (10.65%) | 0.1887 | 1.315 [0.895–1.933] |
HLA-B*14 | 100 (4.9%) | 10 (3.8%) | 0.5354 | 0.763 [0.401–1.450] |
HLA-B*15 | 184 (9.02%) | 19 (7.22%) | 0.4774 | 0.827 [0.522–1.309] |
HLA-B*18 | 405 (19.85%) | 59 (22.43%) | 0.2460 | 1.156 [0.905–1.476] |
HLA-B*35 | 543 (26.62%) | 75 (28.52%) | 0.4085 | 1.095 [0.889–1.348] |
HLA-B*37 | 40 (1.96%) | 4 (1.52%) | 1.000 | 0.814 [0.289–2.273] |
HLA-B*38 | 178 (8.73%) | 26 (9.89%) | 0.4114 | 1.171 [0.787–1.741] |
HLA-B*39 | 104 (5.1%) | 11 (4.18%) | 0.6486 | 0.810 [0.438–1.496] |
HLA-B*40 | 217 (10.64%) | 17 (6.46%) | 0.0287 | 0.596 [0.369–0.962] |
HLA-B*41 | 79 (3.87%) | 12 (4.56%) | 0.7397 | 1.111 [0.611–2.022] |
HLA-B*44 | 383 (18.77%) | 39 (14.83%) | 0.1236 | 0.787 [0.580–1.070] |
HLA-B*47 | 25 (1.23%) | 12 (4.56%) | 0.0007 | 3.705 [1.844–7.441] |
HLA-B*48 | 7 (0.34%) | 3 (1.14%) | 0.1387 | 2.778 [0.723–10.68] |
HLA-B*49 | 67 (3.28%) | 11 (4.18%) | 0.3400 | 1.396 [0.738–2.648] |
HLA-B*50 | 56 (2.75%) | 9 (3.42%) | 0.7031 | 1.122 [0.560–2.250] |
HLA-B*51 | 377 (18.48%) | 38 (14.45%) | 0.1204 | 0.777 [0.572–1.063] |
HLA-B*52 | 118 (5.78%) | 12 (4.56%) | 0.4751 | 0.786 [0.438–1.411] |
HLA-B*53 | 11 (0.54%) | 4 (1.52%) | 0.1292 | 2.357 [0.756–7.351] |
HLA-B*54 | 1 (0.05%) | 2 (0.76%) | 0.0013 | 23.27 [2.428–223.0] |
HLA-B*55 | 62 (3.04%) | 7 (2.66%) | 0.6243 | 0.751 [0.328–1.719] |
HLA-B*56 | 43 (2.11%) | 5 (1.9%) | 1.000 | 0.853 [0.339–2.148] |
HLA-B*57 | 67 (3.28%) | 9 (3.42%) | 1.000 | 0.989 [0.496–1.970] |
HLA-B*58 | 63 (3.09%) | 5 (1.9%) | 0.4253 | 0.648 [0.261–1.624] |
HLA-B*73 | 4 (0.2%) | 0 (0%) | 1.000 | - |
HLA-B | SpA Associations (Independent of HLA-B*27) | Findings from the Romanian Cohort (Our Study) |
---|---|---|
B*07 | axSpA in French (p = 0.0008, OR = 5.91) [15] | No statistical association with SpA (p = 0.146) |
ReA in Americans (28.5% of the B*27-negative) | ||
Idiopathic Sacroiliitis in Americans (50% of the B27 negative) [9] | ||
AS in Black American (p < 0.025) [16] | ||
USpA in Tunisian (p = 0.043, OR = 5.15) [10], Brazilian (p = 0.043, OR = 5.15) [11], Indian (p = 1.14 × 10−7, OR = 5.348) [12] | ||
B*13 | AS in European (p = 0.00429, OR 1.43) [13] | No statistical association with SpA (p = 0.1887) |
PsA in Chinese (p = 4.0 × 10−6, OR 2.65) [17] | ||
B*14 | Spondylarthritis in French (2 members of the same family out of 20 families) [18] | No statistical association with SpA (p = 0.5354) |
AS in Caucasians of European descent (p = 0.08, OR = 1.59) [14], Togolese (p = 0.0005, OR = 69) [19] | ||
B*15 | USpA in Belgian (48%; p < 0.001) [20], Mexican (p<0.01, OR = 3.77) [21], Tunisian (p = 0.002, OR = 18.40) [10] Colombian (p < 0.0001, OR = 20.85) [22] | No statistical association with SpA (p = 0.1887) |
B*18 | PsA in Croatians [23] and Serbian [24] | No statistical association with SpA (p = 0.2460) |
B*35 | Increased risk of sacroiliitis (p = 0.021, OR = 6, 95% CI = 1.3–27), systemic inflammation (p = 0.047, OR= 4.7, 95% CI = 1–11.9), and peripheral arthritis (p = 0.003, OR = 5, 95% CI = 1.75–14.3) in Croatians with USpA [25] SpA in French (p = 0.018) [26] | No statistical association with SpA (p = 0.4085) |
B*38 | AS in Caucasians of European descent (American, British, Australian) (p = 0.04, OR = 3.2) [14] AS in Spanish (p < 0.01, OR = 5.38) [27] | No statistical association with SpA (p = 0.4114) |
PsA in Argentinian (p = 0.03, OR = 2.95) [28], Canadian (p = 0.04) [29] | ||
B*39 | As in Japanese (p = 0.01) [30] | No statistical association with SpA (p = 0.6486) |
PsA in Canadian (p = 0.03) [29] | ||
B*40 | peripheral SpA in French [15] | Protective effect for SpA (p = 0.0287, RR = 1.315 [0.895–1.933]) |
AS in British [31], East Asian–Taiwanese (p < 0.001, OR = 2.8) [32], in an entire cohort of Taiwanese, Chinese, Korean (p = 2.54 × 10−4, OR = 1.65) [33], Caucasians of European descent (p = 0.001, OR = 0.71) [14] | ||
B*49 | AS in European, Asian, African (p = 0.03, OR = 2.36) [14] | No statistical association with SpA (p = 0.1887) |
B*51 | ReA in Tunisian (p = 0.015, OR = 4.91) [10] Behcet in the USA and northern Europe (15%) [34] | No statistical association with SpA (p = 0.1204) |
B*51:01 | AS in Korean [35], European [13] | |
B*52 | AS in Caucasians of European descent (American, British, Australian) (p = 0.006, OR = 2.85) [14] | No statistical association with SpA (p = 0.4751) |
B*57:03 | USpA in Zambian (p < 0.05; OR = 5.24) [36] | No statistical association with SpA (p = 1) |
PsA in Chinese Han (p = 5.8 × 10−5, OR = 20.10) [17] |
SpA | Control #3 | ||||||
---|---|---|---|---|---|---|---|
HLA*B Genotype | Observed Frequency (%) | Theoretical Probability (%) | D | Observed Frequency (%) | Theoretical Probability (%) | D | p-Value |
B*08-B*18 | 4.18 | 1.18 | 3.00 | 2.11 | 0.93 | 1.18 | 0.0606 |
B*07-B*35 | 3.04 | 1.06 | 1.99 | 1.72 | 0.83 | 0.89 | 0.2101 |
B*13-B*35 | 3.04 | 0.80 | 2.24 | 1.03 | 0.63 | 0.40 | 0.0139 |
B*35-B*44 | 3.04 | 1.17 | 1.87 | 2.40 | 1.48 | 0.92 | 0.6761 |
B*15-B*35 | 2.66 | 0.54 | 2.12 | 1.57 | 0.66 | 0.91 | 0.2988 |
B*18-B*51 | 2.66 | 0.91 | 1.75 | 2.30 | 1.02 | 1.28 | 0.8853 |
B*35-B*51 | 2.28 | 1.14 | 1.14 | 2.35 | 1.42 | 0.94 | 0.8853 |
B*07-B*08 | 1.90 | 0.70 | 1.21 | 1.13 | 0.50 | 0.63 | 0.4362 |
B*07-B*18 | 1.90 | 0.84 | 1.06 | 1.32 | 0.60 | 0.73 | 0.636 |
B*07-B*44 | 1.90 | 0.55 | 1.35 | 1.23 | 0.58 | 0.65 | 0.5349 |
B*13-B*18 | 1.90 | 0.64 | 1.26 | 1.08 | 0.45 | 0.62 | 0.3885 |
B*18-B*35 | 1.90 | 1.80 | 0.10 | 2.55 | 1.54 | 1.01 | 0.6704 |
B*44-B*51 | 1.90 | 0.59 | 1.31 | 2.35 | 0.98 | 1.37 | 0.8092 |
B*08-B*08 | 1.52 | 0.98 | 0.54 | 0.54 | 0.78 | −0.24 | 0.1455 |
B*08-B*35 | 1.52 | 1.48 | 0.04 | 2.75 | 1.29 | 1.46 | 0.3334 |
B*08-B*51 | 1.52 | 0.75 | 0.77 | 1.76 | 0.86 | 0.91 | 0.9728 |
B*18-B*38 | 1.52 | 0.61 | 0.91 | 0.83 | 0.47 | 0.36 | 0.4476 |
B*18-B*39 | 1.52 | 0.27 | 1.25 | 0.54 | 0.27 | 0.27 | 0.1455 |
B*18-B*44 | 1.52 | 0.93 | 0.59 | 2.11 | 1.07 | 1.04 | 0.6878 |
B*35-B*35 | 1.52 | 2.26 | −0.73 | 2.60 | 2.13 | 0.46 | 0.3968 |
B*35-B*40 | 1.52 | 0.57 | 0.95 | 1.42 | 0.80 | 0.62 | 0.8823 |
B*08-B*41 | 1.14 | 0.24 | 0.90 | 0.39 | 0.17 | 0.22 | 0.2372 |
B*08-B*44 | 1.14 | 0.77 | 0.37 | 1.72 | 0.90 | 0.82 | 0.6659 |
B*08-B*49 | 1.14 | 0.21 | 0.93 | 0.29 | 0.16 | 0.14 | 0.1221 |
B*35-B*52 | 1.14 | 0.37 | 0.77 | 0.88 | 0.44 | 0.45 | 0.944 |
B*35-B*53 | 1.14 | 0.11 | 1.03 | 0.15 | 0.04 | 0.11 | 0.0197 |
B*38-B*44 | 1.14 | 0.40 | 0.74 | 1.27 | 0.45 | 0.82 | 0.9119 |
B*38-B*51 | 1.14 | 0.39 | 0.75 | 1.18 | 0.43 | 0.74 | 0.7998 |
B*40-B*44 | 1.14 | 0.30 | 0.84 | 1.03 | 0.56 | 0.47 | 0.8766 |
B*44-B*47 | 1.14 | 0.18 | 0.96 | 0.10 | 0.06 | 0.04 | 0.0066 |
B*07-B*38 | 0.76 | 0.36 | 0.40 | 0.34 | 0.25 | 0.09 | 0.62 |
B*07-B*40 | 0.76 | 0.27 | 0.49 | 0.59 | 0.31 | 0.28 | 0.9336 |
B*08-B*13 | 0.76 | 0.53 | 0.23 | 0.83 | 0.38 | 0.45 | 0.811 |
B*08-B*15 | 0.76 | 0.36 | 0.40 | 0.78 | 0.40 | 0.38 | 0.7409 |
B*08-B*38 | 0.76 | 0.51 | 0.25 | 0.78 | 0.39 | 0.39 | 0.7409 |
B*13-B*40 | 0.76 | 0.20 | 0.56 | 0.44 | 0.24 | 0.20 | 0.8168 |
B*13-B*55 | 0.76 | 0.07 | 0.69 | 0.15 | 0.07 | 0.08 | 0.191 |
B*15-B*41 | 0.76 | 0.09 | 0.67 | 0.15 | 0.09 | 0.06 | 0.191 |
B*15-B*50 | 0.76 | 0.06 | 0.70 | 0.20 | 0.06 | 0.13 | 0.295 |
B*18-B*18 | 0.76 | 1.43 | −0.67 | 1.18 | 1.11 | 0.07 | 0.7711 |
B*18-B*41 | 0.76 | 0.30 | 0.46 | 0.34 | 0.20 | 0.14 | 0.62 |
B*18-B*47 | 0.76 | 0.27 | 0.49 | 0.05 | 0.06 | −0.02 | 0.0355 |
B*18-B*49 | 0.76 | 0.25 | 0.51 | 0.25 | 0.19 | 0.06 | 0.4044 |
B*18-B*57 | 0.76 | 0.23 | 0.53 | 0.20 | 0.17 | 0.02 | 0.295 |
B*35-B*38 | 0.76 | 0.77 | −0.01 | 1.08 | 0.65 | 0.43 | 0.8766 |
B*35-B*41 | 0.76 | 0.37 | 0.39 | 0.88 | 0.28 | 0.60 | 0.8788 |
B*35-B*47 | 0.76 | 0.34 | 0.42 | 0.25 | 0.09 | 0.16 | 0.4044 |
B*35-B*49 | 0.76 | 0.31 | 0.45 | 0.49 | 0.26 | 0.23 | 0.9061 |
B*35-B*56 | 0.76 | 0.14 | 0.62 | 0.25 | 0.16 | 0.09 | 0.4044 |
B*38-B*41 | 0.76 | 0.13 | 0.63 | 0.15 | 0.09 | 0.06 | 0.191 |
B*38-B*47 | 0.76 | 0.12 | 0.64 | 0 | 0.03 | −0.03 | 0.0047 |
B*40-B*50 | 0.76 | 0.07 | 0.70 | 0.29 | 0.08 | 0.22 | 0.5138 |
B*44-B*57 | 0.76 | 0.15 | 0.61 | 0.25 | 0.17 | 0.08 | 0.4044 |
B*47-B*51 | 0.76 | 0.17 | 0.59 | 0.15 | 0.06 | 0.09 | 0.191 |
B*51-B*51 | 0.76 | 0.58 | 0.18 | 0.93 | 0.94 | −0.01 | 0.944 |
Number of individuals | n = 263 | n = 2040 | <0.0001 | ||||
HW test | SpA | Control #3 | |||||
P (chi-square) | <0.0001 | <0.0001 |
SpA | Control #3 | ||||||
---|---|---|---|---|---|---|---|
HLA*B Genotype | Observed Frequency (%) | Theoretical Probability (%) | D | SpA Subtype | Observed Frequency (%) | Theoretical Probability (%) | D |
B*13-B*37 | 0.38 | 0.04 | 0.34 | A | 0.00 | 0.04 | −0.04 |
B*13-B*52 | 0.38 | 0.13 | 0.25 | A | 0.00 | 0.13 | −0.13 |
B*18-B*54 | 0.38 | 0.05 | 0.33 | A | 0.00 | 0.00 | 0.00 |
B*47-B*52 | 0.38 | 0.06 | 0.32 | A | 0.00 | 0.02 | −0.02 |
B*38-B*47 | 0.76 | 0.12 | 0.64 | A/M | 0.00 | 0.03 | −0.03 |
B*35-B*48 | 0.38 | 0.09 | 0.29 | M | 0.00 | 0.03 | −0.03 |
B*52-B*53 | 0.38 | 0.02 | 0.36 | M | 0.00 | 0.01 | −0.01 |
B*15-B*48 | 0.38 | 0.02 | 0.36 | P | 0.00 | 0.01 | −0.01 |
B*37-B*41 | 0.38 | 0.02 | 0.36 | P | 0.00 | 0.02 | −0.02 |
B*57-B*57 | 0.38 | 0.04 | 0.34 | P | 0.00 | 0.03 | −0.03 |
HLA*B Genotype | A (%) | M (%) | P (%) | HLA*B Genotype | A (%) | HLA*B Genotype | M (%) | HLA*B Genotype | P (%) |
---|---|---|---|---|---|---|---|---|---|
B*08-B*18 | 1.52 | 1.90 | 0.76 | B*18-B*49 | 0.76 | B*13-B*18 | 1.90 | B*07-B*13 | 0.38 |
B*15-B*35 | 1.14 | 0.76 | 0.76 | B*07-B*51 | 0.38 | B*35-B*35 | 1.52 | B*07-B*14 | 0.38 |
B*07-B*35 | 0.76 | 1.52 | 0.76 | B*07-B*54 | 0.38 | B*35-B*52 | 1.14 | B*07-B*58 | 0.38 |
B*13-B*35 | 0.76 | 0.76 | 1.52 | B*07-B*55 | 0.38 | B*07-B*38 | 0.76 | B*08-B*14 | 0.38 |
B*07-B*08 | 0.76 | 0.76 | 0.38 | B*08-B*52 | 0.38 | B*07-B*40 | 0.76 | B*08-B*50 | 0.38 |
B*07-B*18 | 0.76 | 0.76 | 0.38 | B*13-B*37 | 0.38 | B*13-B*40 | 0.76 | B*13-B*15 | 0.38 |
B*44-B*51 | 0.76 | 0.38 | 0.76 | B*13-B*52 | 0.38 | B*15-B*41 | 0.76 | B*13-B*44 | 0.38 |
B*18-B*38 | 0.76 | 0.38 | 0.38 | B*13-B*58 | 0.38 | B*15-B*50 | 0.76 | B*14-B*51 | 0.38 |
B*18-B*51 | 0.38 | 1.52 | 0.76 | B*14-B*35 | 0.38 | B*18-B*41 | 0.76 | B*15-B*39 | 0.38 |
B*35-B*51 | 0.38 | 1.14 | 0.76 | B*14-B*39 | 0.38 | B*35-B*49 | 0.76 | B*15-B*48 | 0.38 |
B*08-B*08 | 0.38 | 0.76 | 0.38 | B*14-B*50 | 0.38 | B*38-B*41 | 0.76 | B*37-B*41 | 0.38 |
B*08-B*35 | 0.38 | 0.76 | 0.38 | B*18-B*54 | 0.38 | B*51-B*51 | 0.76 | B*37-B*51 | 0.38 |
B*35-B*40 | 0.38 | 0.76 | 0.38 | B*18-B*55 | 0.38 | B*07-B*15 | 0.38 | B*39-B*51 | 0.38 |
B*38-B*44 | 0.38 | 0.38 | 0.38 | B*35-B*50 | 0.38 | B*07-B*39 | 0.38 | B*40-B*40 | 0.38 |
B*35-B*44 | 1.14 | 1.90 | B*35-B*58 | 0.38 | B*07-B*49 | 0.38 | B*40-B*51 | 0.38 | |
B*07-B*44 | 0.76 | 1.14 | B*38-B*49 | 0.38 | B*07-B*52 | 0.38 | B*41-B*44 | 0.38 | |
B*35-B*53 | 0.76 | 0.38 | B*39-B*40 | 0.38 | B*08-B*39 | 0.38 | B*44-B*49 | 0.38 | |
B*18-B*35 | 0.38 | 1.52 | B*39-B*52 | 0.38 | B*08-B*57 | 0.38 | B*44-B*52 | 0.38 | |
B*08-B*49 | 0.38 | 0.76 | B*40-B*56 | 0.38 | B*13-B*14 | 0.38 | B*57-B*57 | 0.38 | |
B*38-B*51 | 0.38 | 0.76 | B*47-B*52 | 0.38 | B*13-B*38 | 0.38 | |||
B*40-B*44 | 0.38 | 0.76 | B*51-B*56 | 0.38 | B*13-B*57 | 0.38 | |||
B*44-B*47 | 0.38 | 0.76 | B*56-B*58 | 0.38 | B*14-B*38 | 0.38 | |||
B*08-B*13 | 0.38 | 0.38 | B*14-B*52 | 0.38 | |||||
B*13-B*55 | 0.38 | 0.38 | B*14-B*57 | 0.38 | |||||
B*18-B*57 | 0.38 | 0.38 | B*15-B*18 | 0.38 | |||||
B*35-B*38 | 0.38 | 0.38 | B*15-B*38 | 0.38 | |||||
B*35-B*41 | 0.38 | 0.38 | B*18-B*40 | 0.38 | |||||
B*35-B*47 | 0.38 | 0.38 | B*18-B*50 | 0.38 | |||||
B*38-B*47 | 0.38 | 0.38 | B*18-B*58 | 0.38 | |||||
B*40-B*50 | 0.38 | 0.38 | B*35-B*48 | 0.38 | |||||
B*08-B*51 | 1.14 | 0.38 | B*35-B*57 | 0.38 | |||||
B*18-B*44 | 1.14 | 0.38 | B*37-B*49 | 0.38 | |||||
B*18-B*39 | 0.76 | 0.76 | B*38-B*38 | 0.38 | |||||
B*08-B*44 | 0.76 | 0.38 | B*38-B*39 | 0.38 | |||||
B*08-B*41 | 0.38 | 0.76 | B*40-B*55 | 0.38 | |||||
B*08-B*15 | 0.38 | 0.38 | B*44-B*55 | 0.38 | |||||
B*08-B*38 | 0.38 | 0.38 | B*48-B*51 | 0.38 | |||||
B*18-B*18 | 0.38 | 0.38 | B*50-B*51 | 0.38 | |||||
B*18-B*47 | 0.38 | 0.38 | B*51-B*55 | 0.38 | |||||
B*35-B*56 | 0.38 | 0.38 | B*52-B*52 | 0.38 | |||||
B*44-B*57 | 0.38 | 0.38 | B*52-B*53 | 0.38 | |||||
B*47-B*51 | 0.38 | 0.38 |
Radiological Sacroiliitis Grade ≥ 2 | No/Sacroiliitis Grade 1 | |||||
---|---|---|---|---|---|---|
HLA*B Genotype | Observed Frequency (%) | Theoretical Probability (%) | D | Observed Frequency (%) | Theoretical Probability (%) | D |
B*08-B*18 | 6.67 | 1.39 | 5.28 | 2.89 | 1.08 | 1.81 |
B*40-B*44 | 3.33 | 0.32 | 3.01 | 0.00 | 0.28 | −0.28 |
B*07-B*44 | 3.33 | 0.64 | 2.69 | 1.16 | 0.49 | 0.66 |
B*35-B*44 | 3.33 | 0.92 | 2.41 | 2.89 | 1.31 | 1.58 |
B*18-B*51 | 3.33 | 0.93 | 2.41 | 2.31 | 0.89 | 1.42 |
B*07-B*18 | 3.33 | 1.23 | 2.10 | 1.16 | 0.67 | 0.49 |
B*40-B*50 | 2.22 | 0.12 | 2.10 | 0.00 | 0.04 | −0.04 |
B*08-B*41 | 2.22 | 0.22 | 2.00 | 0.58 | 0.26 | 0.32 |
B*35-B*47 | 2.22 | 0.28 | 1.94 | 0.00 | 0.37 | −0.37 |
B*18-B*49 | 2.22 | 0.31 | 1.91 | 0.00 | 0.22 | −0.22 |
B*07-B*40 | 2.22 | 0.40 | 1.83 | 0.00 | 0.21 | −0.21 |
B*15-B*35 | 2.22 | 0.43 | 1.80 | 2.89 | 0.61 | 2.28 |
B*44-B*51 | 2.22 | 0.48 | 1.74 | 1.73 | 0.65 | 1.08 |
B*13-B*35 | 2.22 | 0.57 | 1.65 | 3.47 | 0.94 | 2.53 |
B*13-B*18 | 2.22 | 0.62 | 1.60 | 1.73 | 0.63 | 1.10 |
B*35-B*51 | 2.22 | 0.85 | 1.37 | 2.31 | 1.31 | 1.00 |
B*35-B*35 | 2.22 | 1.63 | 0.59 | 1.16 | 2.62 | −1.46 |
Number of individuals | n = 90 | n = 173 | ||||
HW test | Sacroiliitis grade ≥ 2 | No/ sacroiliitis grade 1 | ||||
P (chi-square) | <0.0001 | <0.0001 |
Elevated CRP or ESR | Normal CRP and ESR | |||||
---|---|---|---|---|---|---|
HLA*B Genotype | Observed Frequency (%) | Theoretical Probability (%) | D | Observed Frequency (%) | Theoretical Probability (%) | D |
B*35-B*51 | 5.13 | 1.79 | 3.34 | 1.08 | 0.91 | 0.17 |
B*13-B*35 | 3.85 | 1.07 | 2.77 | 2.70 | 0.69 | 2.01 |
B*08-B*18 | 3.85 | 1.17 | 2.68 | 4.32 | 1.19 | 3.14 |
B*18-B*51 | 3.85 | 1.17 | 2.68 | 2.16 | 0.80 | 1.36 |
B*35-B*44 | 3.85 | 1.19 | 2.65 | 2.70 | 1.13 | 1.57 |
B*18-B*41 | 2.56 | 0.23 | 2.33 | 0.00 | 0.32 | −0.32 |
B*35-B*53 | 2.56 | 0.24 | 2.33 | 0.54 | 0.07 | 0.47 |
B*40-B*44 | 2.56 | 0.25 | 2.32 | 0.54 | 0.32 | 0.22 |
B*07-B*38 | 2.56 | 0.27 | 2.29 | 0.00 | 0.40 | −0.40 |
B*35-B*49 | 2.56 | 0.36 | 2.21 | 0.00 | 0.29 | −0.29 |
B*18-B*39 | 2.56 | 0.39 | 2.17 | 1.08 | 0.22 | 0.86 |
B*15-B*35 | 2.56 | 0.60 | 1.97 | 2.70 | 0.51 | 2.19 |
B*44-B*51 | 2.56 | 0.62 | 1.95 | 1.62 | 0.57 | 1.06 |
B*13-B*18 | 2.56 | 0.70 | 1.86 | 1.62 | 0.61 | 1.01 |
B*35-B*40 | 2.56 | 0.71 | 1.85 | 1.08 | 0.51 | 0.57 |
B*07-B*18 | 2.56 | 0.86 | 1.71 | 1.62 | 0.84 | 0.79 |
B*08-B*08 | 2.56 | 0.92 | 1.64 | 1.08 | 1.00 | 0.08 |
B*07-B*35 | 2.56 | 1.31 | 1.25 | 3.24 | 0.95 | 2.29 |
B*35-B*35 | 2.56 | 3.46 | −0.89 | 1.08 | 1.83 | −0.75 |
Number of individuals | n = 78 | n = 185 | ||||
HW test | Elevated CRP or ESR | Normal CRP and ESR | ||||
P (chi-square) | <0.0001 | <0.0001 |
Population | MICA–HLA-B Haplotype | Frequency (%) |
---|---|---|
USA Caucasian MIC (n = 103) [55] | MICA*002-B*35 | 7.3 |
MICA*007-B*27 | 2.6 | |
MICA*008-B*07 | 8.6 | |
MICA*008-B*08 | 10 | |
MICA*008-B*44 | 8.7 | |
MICA*009-B*35 | 3.1 | |
USA Caucasian MIC pop2 (n = 242) [56] | MICA*002-B*35:01 | 5.3 |
MICA*004-B*44:03 | 4.8 | |
MICA*008-B*07:02 | 12 | |
MICA*008-B*08:01 | 20.6 | |
MICA*008-B*40:01 | 5 | |
MICA*008-B*44:02 | 10.6 | |
MICA*010-B*15:01 | 4.7 | |
MICA*010-B*44:03 | 1.5 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nagit, R.-E.; Pavel-Tanasa, M.; Cianga, C.; Rezus, E.; Cianga, P. Genetic Complexity in Spondyloarthritis: Contributions of HLA-B Alleles Beyond HLA-B*27 in Romanian Patients. Int. J. Mol. Sci. 2025, 26, 7617. https://doi.org/10.3390/ijms26157617
Nagit R-E, Pavel-Tanasa M, Cianga C, Rezus E, Cianga P. Genetic Complexity in Spondyloarthritis: Contributions of HLA-B Alleles Beyond HLA-B*27 in Romanian Patients. International Journal of Molecular Sciences. 2025; 26(15):7617. https://doi.org/10.3390/ijms26157617
Chicago/Turabian StyleNagit, Ruxandra-Elena, Mariana Pavel-Tanasa, Corina Cianga, Elena Rezus, and Petru Cianga. 2025. "Genetic Complexity in Spondyloarthritis: Contributions of HLA-B Alleles Beyond HLA-B*27 in Romanian Patients" International Journal of Molecular Sciences 26, no. 15: 7617. https://doi.org/10.3390/ijms26157617
APA StyleNagit, R.-E., Pavel-Tanasa, M., Cianga, C., Rezus, E., & Cianga, P. (2025). Genetic Complexity in Spondyloarthritis: Contributions of HLA-B Alleles Beyond HLA-B*27 in Romanian Patients. International Journal of Molecular Sciences, 26(15), 7617. https://doi.org/10.3390/ijms26157617